CTOs on the Move

Acucela

www.acucela.com

 
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.acucela.com
  • 1301 2nd Ave # 1900
    Seattle, WA USA 98101
  • Phone: 206.805.8300

Executives

Name Title Contact Details

Similar Companies

The Storch-Murphy Group

The Storch-Murphy Group is a Englewood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inter Valley Health Plan Inc.

Inter Valley Health Plan Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pomona, CA. To find more information about Inter Valley Health Plan Inc., please visit www.ivhp.com

Alivation

Alivation puts you and your family`s health and well-being first. We do this by investing in the latest medical advancements and meticulously staffing the foremost experts in our industry. From basic behavioral health and family health services to in-depth treatments via transcranial magnetic stimulation therapy (TMS) and brain network monitoring, Alivation`s world-class facility and personal approach to your care is second to none. With a full-service pharmacy and research team on-site, Alivation is the only integrated healthcare clinic in the area that`s large enough to provide a high standard of unique care while being small enough to know our patients on a personal level.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.

JUNE

Better alternatives to pads and tampons starting at just $6. The June menstrual cup is a comfortable, easy-to-use alternative that can be safely worn for up to 12 hours. Try it!